Paying for gene therapy: are annuities the next big thing?

February 19, 2015 6:04 AM

3 0

LOS ANGELES (Reuters) - As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines.

The effort, industry executives told Reuters, is being led by firms developing so-called gene therapies, which aim to cure inherited diseases like hemophilia by “fixing” the single faulty gene responsible for the disorder. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sanga...

Also read: Johnny Manziel Agrees to Treatment ... In Domestic Violence Case

Read more

To category page

Loading...